The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•3 March 2026•

1 min read

FDA Backs Atai Life Sciences to Advance Depression Treatment to Phase 3 Trials

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1The FDA supported the Phase 3 design for BPL-003, an intranasal psychedelic-derived therapy for treatment-resistant depression.

Atai Life Sciences (ATAI) has successfully concluded an end-of-phase 2 meeting with the US Food and Drug Administration (FDA) regarding its depression treatment, BPL-003. The regulator provided constructive feedback and support for the Phase 3 clinical trial design for the intranasal psychedelic-derived therapy. This treatment specifically targets treatment-resistant depression, a condition affecting millions of patients who have not responded to standard antidepressants. The FDA's backing includes agreement on the pivotal trial program and safety database requirements for the upcoming study. This milestone significantly de-risks the drug's path to market and marks a critical step forward for the company's clinical pipeline. Investors view this progression as a positive indicator for the company's long-term growth and potential market entry in the biotech sector.